← Browse by Condition
Medical Condition

neuroendocrine carcinoma

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for neuroendocrine carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — neuroendocrine carcinoma Clinical Trials

How many clinical trials are currently recruiting for neuroendocrine carcinoma?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for neuroendocrine carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for neuroendocrine carcinoma?
neuroendocrine carcinoma research spans Phase 1 (1 trial), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a neuroendocrine carcinoma clinical trial?
Eligibility criteria for neuroendocrine carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
1
Top Sponsors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 1 trial
Fudan University 1 trial
Jagiellonian University 1 trial

Recruiting Clinical Trials

NCT06440057 Phase 1, Phase 2
Recruiting
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
Enrollment
78 pts
Location
China
Sponsor
Suzhou Zelgen Biopharmaceutica...
View Trial →
NCT06369181
Recruiting
Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC
Enrollment
50 pts
Location
China
Sponsor
Fudan University
View Trial →
NCT06242119
Recruiting
Clinical Application of the J-PET Scanner Prototype
Enrollment
25 pts
Location
Poland
Sponsor
Jagiellonian University
View Trial →

Related Conditions

non small cell lung cancer (1) histology transformation (1) prostate cancer (1) prostatic hyperplasia (1) prostatic neoplasms (1) prostate cancer metastatic (1) neuroendocrine tumors (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology